2 Concerning Trends That Make Moderna a Risky Buy - The Motley Fool

Next year is going to be challenging for COVID-19 vaccine maker Moderna (MRNA 4.95%).With up to $19 billion in revenue this year potentially coming from its vaccine, there could be a sizable drop ... Read More

Is Moderna a Bad-News Buy for 2025? - The Motley Fool

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said ... Read More

After Moderna's Shocking News, Is the Stock a Buy or a Sell?

Moderna's (MRNA 9.43%) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand for its coronavirus vaccine waned, but seemed ... Read More

Is Moderna a Bad-News Buy for 2025? - AOL

Does all this make Moderna a bad-news buy for 2025? This depends on your comfort with risk. Moderna may reach its product approval and launch goals -- but this will take a few years. Read More

Can Moderna's Aggressive Cost Cuts Help Turn Things ... - The Motley Fool

Moderna (MRNA 0.66%) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future. But you may be surprised to learn that now you can buy the stock around ... Read More

2 Concerning Trends That Make Moderna a Risky Buy | Nasdaq

2 Concerning Trends That Make Moderna a Risky Buy November 17, 2022 — 09:00 am EST Written by David Jagielski for The Motley Fool -> ... Read More

Is Moderna a Bad-News Buy for 2025? - Nasdaq

Does all this make Moderna a bad-news buy for 2025? This depends on your comfort with risk. Moderna may reach its product approval and launch goals -- but this will take a few years. Read More

2 Concerning Trends That Make Moderna a Risky Buy - Yahoo

In the U.S., Moderna projects the COVID vaccine market could be worth between $5.2 billion and $12.9 billion, depending on the price that it obtains per shot. News Today's news ... Read More

Is Moderna a Bad-News Buy for 2025? - Nasdaq

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said ... Read More